Shanghai – September 26, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.
Guangzhou – – September 28, 2026 -- Overseas attendance at the 2026 China (Guangzhou) International Building Decoration Fair reached 11,473 visitors, up 33.4% year on year, with participants drawn from 147 countries and regions despite broader market pressures on the sector.
The 2026 edition wrapped at the Canton Fair Complex with exhibitor growth reported even as the home furnishing and building decoration industry navigates a shift away from a property-driven growth model toward renovation and upgrading. Chen Penghan, Sales Head of CBD Fair, said new opportunities lie in renovation, quality upgrades, intelligent innovation and broader channel development, pointing to early-stage brand globalization, supply-procurement mismatches and incomplete service chains as ongoing challenges.
Calgary, AB – September 28, 2026 -- Canadian Pacific Railway Company (CPRC), the wholly owned subsidiary of Canadian Pacific Kansas City Limited (TSX: CP) (NYSE: CP), is issuing C$1.8 billion in notes across four tranches, guaranteed by parent CPKC.
The offering comprises C$500 million of 4.20% Notes due 2030, C$550 million of 4.60% Notes due 2033, C$300 million of 4.90% Notes due 2037 and C$450 million of 5.40% Notes due 2056. The staggered maturity profile spans 4 to 30 years, giving CPKC a blended long-term debt structure.
CPKC stated the funds will be used primarily for refinancing outstanding indebtedness and for general corporate purposes. Until deployed, unused proceeds may be parked in short-term investment-grade securities, money market funds or bank deposits.
Pittsburgh – September 28, 2026 -- Sharpa unveiled three flagship dexterous-manipulation products at IEEE/RSJ IROS 2026: the D01 integrated robot, the W02 tactile dexterous hand and the AE01 haptic exoskeleton data glove, expanding its hardware portfolio for human-environment robotics.
D01 combines Sharpa Wave dexterous hands with seven-degree-of-freedom arms and whole-body electronic skin. The robot achieves an approximately 1:1 arm payload-to-weight ratio, a maximum end-effector speed exceeding 10.5 meters per second, communication frequency of 1,000 Hz and end-effector repeatability of 0.2 millimeters. Its electronic skin operates at a 100 Hz tactile sampling rate with 0.2 newton force resolution, extending contact sensing across the robot's body.
Syracuse – – September 28, 2026 -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, have launched a proof of concept for FuseRx, a clinical workflow platform for radiation oncology, at AMP's Center of Advanced Radiation Excellence in Syracuse.
The American Cancer Society projects about 333,800 new U.S. prostate cancer cases in 2026, making it the most common cancer in American men after skin cancer. Roughly a third of men with localized disease receive radiation as primary treatment, a pathway that typically starts with a urologist diagnosis before crossing into separate oncology systems.
Singapore – – September 28, 2026 -- The Responsible Fintech Institute (RFI) has appointed Professor Lawrence Loh, Associate Professor Eugene K.B. Tan, Professor Louis Chen and Ms Farah Jaafar as Executive Fellows, while elevating Distinguished Professor Patrick H. M. Loh to Co-Founder.
The nonprofit, based in Singapore, said the appointments deepen its expertise in law, governance, digital policy and cross-border capital markets as regulators and institutions push to ground digital asset, AI and cross-border payment innovation in legal and ethical frameworks.
Washington – September 28, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.
Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.
Hong Kong – – September 28, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) reported a 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) scores from a 28-day U.S. proof-of-concept trial of ASC50, an oral small molecule IL-17A inhibitor positioned as a needle-free alternative to injectable antibody therapies for plaque psoriasis.
The randomized, double-blind, placebo-controlled Phase I study (NCT07024602) enrolled mild-to-moderate plaque psoriasis patients who received once-daily 200 mg oral ASC50 for 28 days. Ascletis said the PASI reduction was comparable to published secukinumab data, though the comparison was not conducted head-to-head.
Göttingen, Germany – September 28, 2026 -- University Medical Center Göttingen (UMG) has become the first hospital in Germany and the European Union to deploy MDClone's ADAMS platform, layering advanced data utilization tools onto its existing UMG-MeDIC data integration center.
ADAMS is already operational at institutions including UChicago Medicine, Manchester University NHS Foundation Trust, and Sheba Medical Center. UMG's rollout marks the model's first entry into a German or EU university hospital, building directly on infrastructure established under Germany's national Medical Informatics Initiative (MII).
London – September 28, 2026 -- UK-based AI platform company askelie has launched askVERA, an AI-powered service that converts complex documents and communications into Plain English and Easy Read formats for consumers and businesses.
The consumer (B2C) version allows individuals to upload or paste documents such as tenancy agreements, insurance policies or official letters to receive an instant simplified version. The business (B2B) version integrates into an organisation's existing workflows, enabling companies to simplify customer-facing content at scale and reduce queries caused by unclear communication.
Ahead of the public launch, askVERA had already been deployed with organisations including Cornwall Council to make official documents more accessible.